# An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

> **NCT07271446** · PHASE1 · COMPLETED · sponsor: **Precision Biotech Taiwan Corp.** · enrollment: 8 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

## Key facts

- **NCT ID:** NCT07271446
- **Lead sponsor:** Precision Biotech Taiwan Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2019-08-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07271446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07271446, "An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07271446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*